Actively Recruiting

Phase 4
Age: 18Years - 80Years
All Genders
NCT07095790

Tirofiban With Sequential Dual Antiplatelet Therapy in Mild Stroke

Led by Second Affiliated Hospital of Soochow University · Updated on 2025-07-31

580

Participants Needed

18

Research Sites

91 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

This study aims to evaluate whether initiating intravenous tirofiban within 48 hours of onset (with a 48-hour infusion), followed by sequential DAPT, can improve the likelihood of excellent functional outcomes (modified Rankin Scale score 0-1) in mild stroke patients, compared with standard DAPT therapy based on current guidelines.

CONDITIONS

Official Title

Tirofiban With Sequential Dual Antiplatelet Therapy in Mild Stroke

Who Can Participate

Age: 18Years - 80Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Age between 18 and 80 years old
  • Acute mild non-cardioembolic ischemic stroke
  • NIHSS score of 5 or less
  • Time from stroke onset or last known well to randomization within 48 hours
  • Ability to receive the investigational drug within 48 hours of symptom onset
  • Signed informed consent by patient or legal representative
Not Eligible

You will not qualify if you...

  • Received or planned intravenous thrombolysis or bridging therapy with endovascular treatment
  • Intracranial hemorrhage confirmed by imaging
  • Pre-stroke modified Rankin Scale score of 2 or higher
  • Any confirmed cardioembolic source such as atrial fibrillation or mechanical heart valve
  • History of primary intracerebral hemorrhage
  • History of other intracranial hemorrhages (intraventricular, subarachnoid, epidural, or subdural)
  • Untreated or inadequately treated intracranial aneurysm or vascular malformation
  • Major systemic bleeding within 30 days
  • Active bleeding or blood clotting problems, including low platelets or recent anticoagulant use
  • Major surgery within 14 days
  • Persistently high blood pressure despite treatment (systolic >180 mmHg or diastolic >110 mmHg)
  • Baseline platelet count below 100 x 10^9/L
  • Severe kidney dysfunction
  • Allergy or contraindication to tirofiban or aspirin
  • Current pregnancy or breastfeeding
  • Any intracranial tumor except small asymptomatic meningiomas
  • Terminal illness with life expectancy less than 6 months

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 18 locations

1

Suzhou Municipal Hospital of Anhui Province

Suzhou, Anhui, China

Actively Recruiting

2

Second Hospital of Hebei Medical University

Shijiazhuang, Hebei, China

Actively Recruiting

3

Taikang Xian People's Hospital

Zhoukou, Henan, China

Actively Recruiting

4

WuYuan County People's Hospital

Bayan Nur, Inner Mongolia, China

Actively Recruiting

5

Huai'an First People's Hospital

Huai'an, Jiangsu, China

Actively Recruiting

6

Jiangsu Province (Suqian) Hospital

Suqian, Jiangsu, China

Actively Recruiting

7

Second Affiliated Hospital of Soochow University

Suzhou, Jiangsu, China, 215004

Actively Recruiting

8

Affiliated Jiangsu Shengze Hospital of Nanjing Medical University

Suzhou, Jiangsu, China

Actively Recruiting

9

Changshu No.1 People's Hospital

Suzhou, Jiangsu, China

Actively Recruiting

10

First People's Hospital of Kunshan

Suzhou, Jiangsu, China

Actively Recruiting

11

Suzhou Ninth People's Hospital

Suzhou, Jiangsu, China

Actively Recruiting

12

Suzhou Xiangcheng People's Hospital

Suzhou, Jiangsu, China

Actively Recruiting

13

Taicang TCM Hospital Affiliated to Nanjing University of Chinese Medicine

Suzhou, Jiangsu, China

Actively Recruiting

14

Zhangjiagang Hospital of Traditional Chinese Medicine

Suzhou, Jiangsu, China

Actively Recruiting

15

Taixing Second People's Hospital

Taizhou, Jiangsu, China

Actively Recruiting

16

Nuclear Industry 417 Hospital

Xi'an, Shaanxi, China

Actively Recruiting

17

First People's Hospital of Xianyang

Xianyang, Shaanxi, China

Actively Recruiting

18

Second Hospital of Tianjin Medical University

Tianjin, China

Actively Recruiting

Loading map...

Research Team

J

Jijun Shi, M.D

CONTACT

Y

Yongjun Cao, M.D, PhD

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

SINGLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here

Tirofiban With Sequential Dual Antiplatelet Therapy in Mild Stroke | DecenTrialz